Evotec joins iCARE4CVD a consortium to personalise prevention and treatment of cardiovascular diseases

Hamburg, Germany, 26 October 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its participation in iCARE4CVD, an international public-private research consortium iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) to better understand cardiovascular disease and optimise future prevention and treatment. The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk.

Cardiovascular disease is very prevalent worldwide with enormous socio-economic impact. It is still the most common cause of death, despite significant advances in therapy. Due to population ageing and unhealthy lifestyle, the number of Europeans suffering from CVD currently exceeds 85 million and is still on the rise. This underscores the critical need for better care pathways to reduce the impact of CVD.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec SE, commented: “We are thrilled to support iCARE4CVD in enhancing cardiovascular care pathways through impactful collaborations. The focus on creating validated prediction models using biomarkers and predictive algorithms, tailored to individual patient responses, aligns seamlessly with our expertise in data-driven research and innovative technologies and expertise in cardiovascular disease and comorbidities, including renal and metabolic disorders. Together, we aim to develop cutting-edge pharmaceutical solutions, ensuring effective for the right patient at the right time worldwide.”

iCARE4CVD has been granted € 22 m in funding from the Innovative Health Initiative ("IHI") - a joint undertaking of the European Commission and the European life science industry. The project officially kicked off its activities across Europe in October 2023 and will run until 31 March 2028.

Please follow this link to the full press release published by the consortium.


This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.